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Porcine circovirus type 2 (PCV2) is the primary causative agent of an emerging swine disease, postweaning multisystemic wasting syndrome
(PMWS) for which no antiviral treatment is available. To exploit the possibility of using RNA interference (RNAi) as a therapeutic approach
against the disease, plasmid-borne short hairpin RNAs (shRNAs) were generated to target the PCV2 genome. Transfection of these shRNAs into
cultured PK15 cells caused a significant reduction in viral RNA production that was accompanied by inhibiting viral DNA replication and protein
synthesis in infected cells. The effect was further tested in vivo in a mouse model that has been developed for PCV2 infection. Mice injected with
shRNA before PCV2 infection showed substantially decreased microscopic lesions in inguinal lymph nodes compared to controls. In situ
hybridization and immunohistochemical analyses showed that shRNA caused a significant inhibition in the level of viral DNA and protein
synthesis detected in the lymph nodes of the treated mice relative to the controls. Taken together, these results indicate that shRNAs are capable of
inhibiting PCV2 infection in vitro as well as in vivo and thus may constitute an effective therapeutic strategy for PCV2 infection.
D 2005 Elsevier Inc. All rights reserved.Keywords: Porcine circovirus type 2 (PCV2); RNA interference (RNAi); shRNA; DNA replication; Protein synthesis; MouseIntroduction
Postweaning multisystemic wasting syndrome (PMWS) is a
new emerging disease affecting pigs primarily at 5 to 18 weeks
of age. This disease was first identified within high-health
herds in Western Canada in 1991 (Clark, 1997) and now is
considered to be endemic in many swine-producing countries
of the world (Allan and Ellis, 2000). Pigs affected with PMWS
show weight loss, dyspnea, tachypnea, anemia, diarrhea, and
jaundice. Characteristic macroscopic findings are enlargement
of lymph nodes and noncollapsed lungs with tan mottling.
Microscopic lesions can be detected in a number of tissues, the
most characteristic being those of lymphoid tissues. These
lesions consist of lymphocyte depletion of follicular and
interfollicular areas together with macrophage infiltration of
lymphoid tissues. Other common lesions described for PMWS
include interstitial pneumonia, periportal to diffuse hepatitis,
and interstitial nephritis (Clark, 1997; Rosell et al., 1999).0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: kwang@tll.org.sg (J. Kwang).Isolation of virus from tissues of affected pigs led to the
identification of a porcine circovirus type 2 (PCV2), consid-
ered to be of etiological importance in PMWS (Allan et al.,
1999; Ellis et al., 1998; Hamel et al., 1998; Meehan et al.,
1998; Morozov et al., 1998). Porcine circovirus type 1 (PCV1)
was originally identified as a contaminant of porcine kidney
cell cultures (PK15 ATCC CCL-33) (Tischer et al., 1982) and
is nonpathogenic to pigs (Allan et al., 1995; Tischer et al.,
1982).
Porcine circovirus (PCV) is classified in the genus
Circovirus of the Circoviridae family (Pringle, 1999). The
PCV virion is icosahedral, non-enveloped, and 17 nm in
diameter. The genome of PCV is a single-stranded circular
DNA of about 1.76 kb. The overall DNA sequence homology
within the PCV1 or PCV2 isolates is greater than 90%, while
the homology between PCV1 and PCV2 isolates is 68–76%.
Two major open reading frames (ORFs) have been recognized
for PCV, ORF1, called rep gene, which encodes a protein of
35.7 kDa involved in virus replication (Mankertz et al., 1998),
and ORF2, called cap gene, which encodes the major
immunogenic capsid protein of 27.8 kDa (Cheung, 2003a;
Nawagitgul et al., 2000). In addition to the replicase ORF1 and6) 422 – 433
www.e
J. Liu et al. / Virology 347 (2006) 422–433 423the capsid protein ORF2, a novel protein, ORF3, has been
detected in PCV2 productive infection and is not essential for
PCV2 replication in cultured cells but is involved in virus-
induced apoptosis (Liu et al., 2005). ORF2 protein has been
demonstrated to stimulate protective responses to injected pigs
with baculovirus-expressed product or DNA prepared from the
gene (Blanchard et al., 2003; Kamstrup et al., 2004).
Furthermore, other studies have shown that chimeric PCV1–
2 virus with the immunogenic ORF2 capsid gene of pathogenic
PCV2 cloned into the nonpathogenic PCV1 genomic backbone
as well as an attenuated PCV2 after 120 passages could induce
specific antibody responses (Fenaux et al., 2004a, 2004b).
However, there is a great need for the development of a new
therapy for PCV2 infection.
RNA interference (RNAi) is a natural process by which
double-stranded RNA directs sequence-specific post-transcrip-
tional gene silencing (Fire, 1999; Hammond et al., 2001a,b;
Sharp, 2001). Specific inhibition of endogenous or pathogen
mRNA by RNAi can be triggered by the introduction of 21–
23 nucleotide (nt) duplexes of RNA (siRNA) or by transcrip-
tion of DNA precursor into short hairpin RNAs (shRNA)
homologous to target sequences (Brummelkamp et al., 2002;
Elbashir et al., 2001a; Paddison et al., 2002), opening up
possibilities for controlling replicative processes of pathogens.
This discovery promoted the use of RNAi for specifically
inhibiting gene expression and replication of infectious
viruses. Over the past years, RNAi approaches have shown
to be effective against a variety of viruses in cell culture,
among these are prominent viruses such as human immuno-
deficiency virus 1 (Capodici et al., 2002), influenza virus (Ge
et al., 2003), poliovirus (Gitlin et al., 2002), severe acute
respiratory syndrome virus (Wang et al., 2004), herpes virus
(Jia and Sun, 2003), human papillomavirus (Hamel et al.,
1998), dengue virus (Caplen et al., 2002), and West Nile virus
(McCown et al., 2003). Synthetic siRNAs as well as shRNAs
transcribed in vivo from DNA templates have been shown to
be potent inhibitors of gene expression in adult mice
(McCaffrey et al., 2003). Studies in mice injected with
shRNAs or siRNAs directed against hepatitis B virus have
raised expectations about the use of RNAi as an antiviral
strategy (Giladi et al., 2003; McCaffrey et al., 2003).
Furthermore, siRNAs or DNA vectors produced shRNAs have
also been shown to reduce the influenza viral load in murine
lungs and increase survival (Ge et al., 2004; Tompkins et al.,
2004). Recently, there is a report that administration of
siRNAs to mice before West Nile virus infection has reduced
the viral load and offered partial protection from lethal
infection (Bai et al., 2005). PCV2 has been demonstrated to
cause lymphoid lesions of infected BALB/c mice characterized
by expansion of germinal centers in lymphoid organs with
large numbers of histiocytic cells and lymphoblasts, apoptosis
of histiocytic cells, and lymphoid depletion (Kiupel et al.,
2001), which is consistent with that of PCV2-infected pigs.
Therefore, this model system offers the opportunity to test the
ability of RNAi to inhibit replication of PCV2 in vivo.
Here, we report that shRNAs directed against the PCV2
ORF1 and ORF2 regions are capable of efficiently inhibitingviral replication and protein synthesis both in PK15 cell culture
system as well as in the mouse model.
Results
Inhibition of PCV2 viral protein synthesis in cell culture by
shRNA is sequence-specific and dose-dependent
To test whether RNAi could inhibit PCV2 in cell culture, we
generated six shRNA-expressing plasmids targeting the ORF1
and ORF2 regions of the PCV2 genome (Fig. 1A) for their
ability to suppress expression of PCV2 viral proteins. The
PK15 cells were transfected with the shRNA-expressing
plasmids and then infected with PCV2, and the levels of
PCV2 viral protein production were determined by IFA at 48
h after infection. The time points for measuring the effects of
shRNA in cells were chosen following preliminary optimiza-
tion experiments (data not shown). To confirm the specificity
of the inhibition, pVP2, an shRNA-expressing plasmid directed
against porcine parvovirus viral sequence, was used as a
negative control in the experiments. The results showed that all
shRNA-expressing plasmids targeting the PCV2 genome
caused a decrease in PCV2 antigen levels to varying degrees
(Figs. 1B and C). Among these specific shRNAs, pSIR3 and
pSIR6 exhibited the highest level of inhibition (Figs. 1B and
C). Therefore, we chose these two shRNA-expressing plasmids
for the following experiments. In contrast to the PCV2-specific
shRNAs, the control pVP2 had no effect on PCV2 antigen
level in the treated cells, indicating that inhibition by the
PCV2-targeted shRNAs was specific and due to RNAi.
A dose–response analysis (Fig. 2A) was conducted by
transfecting PK15 cells with increasing amounts of pSIR3,
pSIR6, or negative control pVP2-expressing plasmid followed
by measuring the numbers of PCV2 antigen cells by IFA 72
h post-transfection. The results showed that, at concentrations
of 1500 to 2500 ng shRNA-expressing plasmid per 5  104
cells, the highest level of inhibition (fivefold) of viral antigen
was obtained with pSIR3 and pSIR6 plasmids, whereas pVP2
had no effect (Fig. 2A). At higher doses of shRNA, we
observed a slight nonspecific inhibitory effect of pVP2 on viral
protein production (Fig. 2A). In addition, kinetic study results
(Fig. 2B) revealed a continuous trend in the specific inhibition
of PCV2 viral production by pSIR3 and pSIR6 from 48 to 120
h after transfection. The inhibition of PCV2 viral production
was maximal at 72 h but thereafter started to decline by 96
h after transfection.
Inhibition of PCV2 viral transcription and DNA replication by
shRNAs in cell culture
To confirm that the effect of pSIR3 and pSIR6 on PCV2
viral production was through the reduction of PCV2 RNA
levels, we performed real-time RT-PCR analysis with RNA
extracted from PK15 cells 72 h after transfection with pSIR3,
pSIR6, and pVP2-expressing plasmid, respectively. The
amount of each viral mRNAwas normalized to that of GAPDH
mRNA in the same sample. The abundance of ORF1 and
Fig. 1. Inhibition of PCV2 protein synthesis in cell culture by different shRNA-expressing plasmids. (A) Schematic representation of the sites of the six shRNA target
sequences against genomic DNA of PCV2 strain BJW. (B) PK15 cells (5  104) were transfected with 1.5 Ag of each shRNA-expressing plasmids followed by
infection with PCV2 at an MOI of 1 TCID50 at 24 h post-transfection. The proportion of cells that were positive for PCV2 was determined by an indirect
immunofluorescence analysis 48 h after infection and is depicted as a percentage of PCV2 positive signals in PCV2-alone-infected cells (control). pVP2 plasmid is a
negative control. The data shown are mean values T SD based on three independent experiments.
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cells transfected with pSIR3- or pSIR6-expressing plasmids
(Fig. 3A). shRNAs are known to be incorporated into an RNA-
induced silencing complex and to direct RNA-induced
silencing complex-mediated sequence-specific mRNA degra-
dation (Hammond et al., 2000). ORF1 and ORF2 of PCV2
have been demonstrated to contain different mRNA, but their
mRNA levels were reduced in the PCV2-infected cells
regardless of ORF1 or ORF2 shRNA transfection. One
possible explanation for the effects of this coordination is that
the target mRNA bound with a shRNA might affect the other
non-target mRNA of the virus through a downstream effect on
all the viral transcripts because viral replication is inhibited, but
the detailed mechanism of this process remains unclear.
To further study the inhibitory effect of pSIR3- or pSIR6-
expressing plasmids on PCV2 DNA replication, the super-
natants of infected PK15 cells after being transfected with the
shRNA plasmids at 72 h post-transfection were directly
assayed by PCR amplification with primers 1446F and 420R.
The results showed that reduced level of newly synthesized
viral replicative form (RF) DNA was observed in the treated
cells with pSIR3- or pSIR6-expressing plasmids (Fig. 3B). In
contrast, the viral RF DNA was detected in the treated cells
with the control pVP2-expressing plasmid as seen in that of
PCV2-alone-infected cells (Fig. 3B).
Effects of mutations on antiviral activity of shRNA
To further examine the ability of ORF1 shRNA to suppress
viral gene expression in PCV2-infected PK15 cells, singlenucleotide mutations were introduced into pSIR3 sequence as
shown in Fig. 4A. Cells were infected with PCV2 after being
transfected with these shRNA-expressing plasmids, and total
proteins were extracted and examined by an immunoblot
analysis with mouse polyclonal antibody against ORF1 or
ORF2 protein at 48 h post-infection. The cells transfected with
pSIR3- or pSIR6-expressing plasmid manifested a marked
depletion of viral proteins compared with cells transfected with
pVP2-expressing plasmid (Fig. 4B). While extinctions of the
ORF1 and ORF2 protein expression were observed in the
pSIR3 plasmid-treated cells, a significant suppression of ORF2
protein expression and noticeable decreases in the level of the
ORF1 protein were detected after the pSIR6 treatment. In
addition, drastic suppression or not was detected in the mutant
shRNA-expressing plasmids dependent on the location of
mutation in the RNAi sequence. As shown in Fig. 4B, a mutant
with one nucleotide mutation in the 5V-end of the sense strand
(pSIR3-m1) still had an effective reduction in the synthesis of
ORF1 and ORF2 proteins, whereas with a nucleotide substi-
tution at the center (pSIR3-m2) or 3V-end (pSIR3-m3) of the
sense sequence, the resultant shRNAs failed to significantly
suppress expression of PCV2 ORF1 and ORF2 in the
transfected cells, further verifying the specificity of RNAi as
demonstrated (Amarzguioui et al., 2003; Harborth et al., 2003).
Neither viral infection nor treatment with shRNA alone
influenced the level of GAPDH production (Fig. 4B).
We also examined the effects of pSIR3 and pSIR6 as well as
mutated shRNAs by FACS with porcine antibody raised
against PCV2 72 h after shRNA-expressing plasmids transfec-
tion. As shown in Fig. 4C, PCV2 viral production was
Fig. 2. pSIR3 and pSIR6 interfere with viral protein synthesis in cell culture.
(A) Dose-dependent inhibition of PCV2 protein synthesis. PK15 cells (5  104)
were transfected with the indicated amounts of the PCV2 ORF1 or ORF2
shRNA and the irrelevant shRNA followed by infection with PCV2 at an MOI
of 1 TCID50 at 24 h post-transfection and assayed for the amount of PCV2 viral
antigen at 48 h post-infection by IFA. (B) Kinetics of inhibition of PCV2
protein synthesis by shRNAs. PK15 cells (5  104) were infected with PCV2
after being transfected with 1.5 Ag of pSIR3 or pSIR6 as well as the negative
control pVP2-expressing plasmids at 24 h post-transfection. The levels of
PCV2 protein synthesis were measured by IFA at 36, 48, 72, 96, 120, and 144
h post-transfection. The amounts of PCV2 viral antigen are shown as
percentages of the PCV2-positive signals in mock-transfected cells (control).
The data represent the mean values T SD of three independent experiments
performed.
Fig. 3. Inhibition of PCV2 viral transcription and DNA replication by shRNA-
expressing plasmids in cell culture. (A) The effects of shRNA on PCV2 mRNA
levels. Total RNAs isolated from PCV2-infected cells 72 h after transfection
with the pSIR3 and pSIR6 shRNAs were subject to a real-time RT-PCR
analysis of ORF1 and ORF2 mRNAs. The data were normalized to the amount
of GAPDH mRNA and are expressed as percentages of the normalized value
for PCV2-infected cells in mock-transfected cells (control); they are means T
SD of values from at least three independent experiments. (B) PCR analysis
performed on DNA extracted from the supernatants of infected PK15 cells after
being transfected with the indicated shRNAs 72 h post-transfection. The
shRNA plasmid used for each transfection is indicated on top of each lane.
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pSIR3- or pSIR6-expressing plasmids. In addition, the pSIR3-
m1 significantly suppressed PCV2 protein synthesis, whereas
the two other shRNA mutants (pSIR3-m2 and pSIR3-m3) had
no effect (Fig. 4C), indicating that the effects of PCV2 shRNAs
are indeed highly specific. As expected, the pVP2 shRNA also
did not inhibit PCV2 viral expression (Fig. 4C).
Attenuation of PCV2-induced pathology in mice by shRNA
To determine whether shRNAs exert an antiviral response in
vivo in BALB/c mice, we administered the pSIR3 or pSIR6
plasmids 1 day before viral inoculation. No clinical signs or
gross lesions were observed in shRNA-expressing plasmids
transfected or mock-transfected mice that received PCV2 at
any time during the 12-day observation period. Microscopic
alterations in PCV2 alone mice were first noticed at day 5 post-
infection, slight germinal centers developed in the parenchyma
of the inguinal lymph nodes (data not shown). At 11 days post-infection, the mice developed prominent germinal centers that
consisted of large lymphoblastic cells and histiocytic cells, and
the paracortex had loss of lymphocytes and was infiltrated by
large numbers of histiocytes (Fig. 5A). In contrast, the lymph
nodes showed normal microscopic morphology in treated mice
with pSIR3 or pSIR6 at 5 days post-infection as seen in that of
mock-infected mice (data not shown). At 11 days post-
infection, mice treated with pSIR3 or pSIR6 showed signifi-
cantly lower (P < 0.05) lesion scores than that of untreated
mice and showed a considerable reduction in inguinal lymph
Fig. 5. shRNAs mediate attenuation of PCV2 infection in mice. Histology (staining with hematoxylin and eosin) of inguinal lymph node sections of mice with
pSIR3, pSIR6, or control pVP2, at day 11 after infection. (A) Prominent germinal centers occupy most of the parenchyma in PCV2-infected control. (B and C)
Showed normal morphology of inguinal lymph nodes after transfection with pSIR3 or pSIR6, respectively. No germinal centers were noticeable. (D) No germinal
centers are noticeable in negative control. Scale bar, 200 Am.
Fig. 4. Effects of mutated pSIR3 on PCV2 protein synthesis in cell culture. (A) Sequences of the position of each mutation in the pSIR3 region. The targeting sequence
for pSIR3 is listed at the top. The sequences of wild-type and mutated shRNAs are shown, with mutated nucleotides underlined. (B) Whole-cell extracts prepared from
transfected PK15 cells 72 h after treatment with the indicated shRNA-expressing plasmids were assayed by Western blotting for the presence of ORF1 and ORF2
expression in PCV2-infected cells. GAPDHwas used as the loading control. (C) PK15 cells transfected with the indicated shRNAs were infected with PCV2 24 h later.
PCV2 protein expression was measured by flow cytometry with porcine antibody against PCV2 72 h after transfection. Graphic key: black (filled), mock-infected
control; gray (line), shRNA transfection; black (line), PCV2 infection without shRNA infection. Representative FACS plots from one of three experiments are shown.
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in the number of infiltrating histiocytes compared to controls
(Figs. 5B and C). In addition, the nonspecific pVP2 shRNA did
not attenuate the lymph node lesions induced by PCV2
infection at 5 and 11 days post-infection (data not shown).
No microscopic lesions were observed in mock-infected mice
(Fig. 5D). The results suggest that PCV2 shRNA can
significantly attenuate PCV2-induced lymph node pathology
in mice.
Inhibition of PCV2 DNA replication in mice by shRNA
To further study the effect of pSIR3 or pSIR6 on viral DNA
replication in vivo, we performed an in situ hybridization
analysis with inguinal lymph nodes of mice treated with
shRNAs at 6 and 12 days after injection. Replicated PCV2
genomic DNA was present in 2.0 T 0.5% of infected cells in
inguinal lymph node sections of mice that received PCV2Fig. 6. The effects of shRNA on PCV2 viral replication in mouse inguinal lymph n
mice with pSIR3, pSIR6, or control pVP2, at day 11 after infection. Hybridization s
pSIR3 or pSIR6 reduces the number of cells that stain for PCV2 nucleic acids. Repr
signals are seen in most fields. (B) Partial enlargement of panel A. (C) pSIR3, no h
indicated. (E) Control pVP2, hybridization signals can be seen as mock-transfected
observed. Scale bar, 80 Am.alone at 6 days after injection, with slight inhibitory effect
observed in the pSIR3 or pSIR6-treated mice (data not shown).
At 12 day post-injection, PCV2 nucleic acid was detected in
8.2 T 1.5% of infected cells such as macrophages, histiocytes,
and occasional lymphocytes in inguinal lymph node tissue
sections from mice that were inoculated with PCV2 alone.
Positive cells typically exhibited a dark purple to black reaction
product in the cytoplasm as well as in the nucleus (Figs. 6A
and B). Lymph node sections from mice receiving pSIR3 had
significantly reduced numbers of positive cells (P < 0.05), with
1.2 T 0.5% of stained cells (Fig. 6C). The number of stained
cells in sections from pSIR6-treated mice was also significantly
reduced (P < 0.05, 1.6 T 1.2% of infected cells) (Fig. 6D). In
contrast, the number of positive cells in sections of mice treated
with pVP2 RNAi did not show any reduction (P > 0.05, 8.5 T
2.3%) (Fig. 6E). No staining was seen in sections from mock-
infected mice (Fig. 6F). These results demonstrate that PCV2
shRNA can inhibit the PCV2 DNA replication in vivo.ode sections. In situ hybridization staining of inguinal lymph node sections of
ignals for PCV2 nucleic acids are seen as purple color (arrow). Treatment with
esentative sections are shown. (A) Mock-transfected group, many hybridization
ybridization signals were observed in most fields. (D) pSIR6, few signals were
group. (F) Lymph node section from a normal mouse, no positive signals were
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We also assessed the effect of shRNA on PCV2 protein
synthesis by immunohistochemical staining for PCV2 in
inguinal lymph node sections from mice treated in the
experiment described above. At 6 days after injection of the
shRNAs followed by inoculation of PCV2, the numbers of cells
stained positively for PCV2 in PCV2-alone-infected group were
2.5 T 0.6%, with slight inhibitory effect observed in the pSIR3-
or pSIR6-treated mice (data not shown). As shown in Figs. 7A
and B, the numbers of PCV2 antigen-positive cells increased
significantly in the inguinal lymph nodes of the virus-inoculated
cells at 12 days after injection (P < 0.05, 8.9 T 2.1%), but mice
treated with pSIR3 or pSIR6 exhibited small increase in PCV2
antigen-positive cells (1.5 T 0.4% for pSIR3 or 1.8 T 0.7% for
pSIR6 treatment) (Figs. 7C and D) and, thus, overall had a
significant inhibition (P < 0.05) compared to the virus-
inoculated alone mice. PCV2 staining was detected mainly in
the cytoplasm but for some in the nucleus as well. As a control,Fig. 7. The effects of shRNA on PCV2 protein synthesis in inguinal lymph node se
with pSIR3, pSIR6, or control pVP2, at day 11 after infection. PCV2 antigen-positiv
the number of cells that stain for PCV2 antigen. Representative sections are shown. (
Partial enlargement of panel A. (C) pSIR3, no stained cells were observed in most f
cells can be seen as mock-transfected group. (F) Lymph node section from a normmice treated with pVP2 showed similar PCV2-positive cells
(8.7 T 2.2%) to the virus control at 12 days after injection
(Fig. 7E). No staining was seen in sections from mice that were
not inoculated with PCV2 (Fig. 7F). The results emphasized
the significant antiviral activity of the pSIR3 and pSIR6 and
their ability to suppress PCV2 protein synthesis in vivo.
Discussion
RNAi operates at the post-transcription level to suppress gene
expression and has developed into a powerful method to down-
regulate the expression of endogenous as well as exogenous
sequences of the cell (McManus and Sharp, 2002; Morris et al.,
2004). The ability to silence mammalian gene expression using
siRNA opens new and exciting routes to the understanding of
mammalian cell biology and its pathology. There are many
precedents for RNAi being effective against a wide range of viral
pathogens in vitro. In addition, RNAi has been demonstrated to
be functional in mice and can inhibit viral replication andctions. Immunohistochemical staining of inguinal lymph node sections of mice
e cells are seen as brown color (arrow). Treatment with pSIR3 or pSIR6 reduces
A) Mock-transfected group, many positive cells for PCV2 antigen are seen. (B)
ields. (D) pSIR6, faintly stained cells were indicated. (E) Control pVP2, stained
al mouse, no staining was observed. Scale bar, 80 Am.
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B and influenza viruses (Ge et al., 2004; Giladi et al., 2003;
McCaffrey et al., 2003; Uprichard et al., 2005). These studies
have shown that RNAi can potentially be used as a therapeutic or
prophylactic mechanism against viruses. Here, we have provid-
ed evidence that shRNAs targeting the ORF1 and ORF2 regions
of PCV2 are capable of inhibiting all the steps of PCV2 infection
in cultured cells, which support viral production, and in vivo in a
mouse model.
In PCV2, three ORF regions have been recognized. In this
study, to test which region of the PCV2 genome is the most
effective site for siRNA targeting, six different anti-PCV2
shRNAs were selected at the ORF1 and ORF2 genes that have
important functions in viral replication and production, respec-
tively. After testing the effect of these vector-based siRNAs on
the inhibition of PCV2 replication in cultured PK15 cells, we
found that all six shRNAs could cause a decrease in PCV2
replication to varying degrees, with two of them being more
effective. These results may be due to different positional
accessibility caused by steric hindrance by a secondary or
tertiary structure and/or protein binding (Kamstrup et al., 2004).
We also noticed that the nonspecific pVP2-expressing plasmid
has some inhibitory effect on PCV2 replication after being
transfected at higher concentration. This could be due to the non-
gene-specific suppression of siRNA. Higher concentrations of
siRNA have been demonstrated to exhibit more measurable
nonspecific gene suppression activity (Persengiev et al., 2004).
Therefore, identifying highly active siRNAs and decreasing
siRNA concentrations can alleviate some nonspecific effects
while maintaining efficient silencing.
It has been thought that siRNAs target mRNAs containing
the same sequences and induce their cleavage. In this study,
we used real-time RT-PCR to detect ORF1 or ORF2 mRNA
level after being transfected with pSIR3- or pSIR6-expres-
sing plasmids and found that not only can shRNA
significantly reduce its corresponding mRNA level but
inhibit other viral gene transcription as well (Fig. 3A). This
could be related to the life cycle of the virus. It can be
assumed that the PCV2-specific shRNA first recognizes the
corresponding sequence of the viral mRNA and initiates the
degradation of this mRNA. As a consequence, the degrada-
tion of the mRNA results in blockage of the corresponding
protein synthesis, i.e., silencing of viral gene expression.
Thus, the amount of newly synthesized mature virions might
have been reduced in the subsequent virus infection.
Therefore, significant inhibition in other mRNA level could
be due to reduction of newly synthesized mature virions
induced by shRNA when it does not directly target this
mRNA. This hypothesis has been further confirmed by the
data that viral DNA was reduced in supernatants of
transfected cells (Fig. 3B) and PCV2 protein synthesis was
inhibited in transfected cells (Fig. 4C).
The roles of siRNA target recognition have been examined
employing diverse siRNAs with nucleotide substitutions
(Amarzguioui et al., 2003; Chiu and Rana, 2003; Elbashir et
al., 2001b; Harborth et al., 2003; Pusch et al., 2003).
Introducing a single nucleotide change to the siRNA sequencecould abrogate siRNA-mediated silencing. To clarify this
question, we performed evaluations using a series of pSIR3
mutants containing point mutations at different locations. The
data (Figs. 4B and C) suggest that point mutations in the
middle and 3V-end sequence of pSIR3 sense strand could
eliminate the anti-PCV2 activity probably due to a decrease in
the affinity of the siRNA for the target mRNA (Schwarz et al.,
2003), whereas the point mutation of the 5V-end sequence did
not interfere with the antiviral activity. Sequence specificity of
siRNA is very stringent as single base pair mismatches
between the siRNA and its target sequence can dramatically
reduce the silencing capability (Elbashir et al., 2001a, 2001b;
Yuan et al., 2005). However, the molecular mechanism of this
phenomenon needs to be further studied. In addition, it has
been demonstrated that escaping mutants were generated
following siRNA or shRNA treatment (Boden et al., 2003;
Gitlin et al., 2002, 2005), this can be prevented by treatment
with multiplex specific siRNAs or targeting long portions of
the viral genome. In this study, we also performed three
passages of PCV2 on newly pSIR3-expressing plasmid-
transfected cells to investigate whether escaping PCV2 mutants
were generated, but did not detect any mutants (data not
shown), suggesting that the pSIR3 targeting sequence is a
critical site for the fitness of the virus. Therefore, this kind of
targeting sequence as pSIR3 can be used as targets for
designing siRNA in PCV2 therapy.
A few studies have addressed the potential of siRNA-based
therapeutics in vivo using model animal systems. Interference
with transgene and endogenous gene expression in mice
following administration of siRNA duplexes has been reported
(McCaffrey et al., 2002; Song et al., 2003). To prolong the
expression of siRNA, a plasmid or an integrating viral vector
expressing endogenous siRNA can be used to achieve this
purpose (McCaffrey et al., 2003; Uprichard et al., 2005). Such
vector-based strategies with generation of siRNA may be used
to test inhibition or suppression of viral gene expression and
replication in animal models and permit greater understanding
of the role and activity of viral genes in vivo. By contrast to
that PCV2 was capable of replicating in BALB/c mice and
caused microscopic lesions (Kiupel et al., 2001), Quintana et
al., (2002) reported that no microscopic lesions compatible
with PCV2 infections in pigs were detected in inoculated mice,
but it might be due to the inoculum of the dosage and
administration route (Quintana et al., 2002). In the present
study, we observed enlargement of germinal centers by
infiltration with large numbers of lymphoblastic and histiocytic
cells, apoptosis of histiocytes, and lymphocytic depletion in the
paracortex of lymph nodes in PCV2-inoculated BALB/c mice
(Fig. 5A and data not shown) which resembled early lesions in
lymph nodes in PCV2-inoculated gnotobiotic pigs. Further-
more, PCV2 replication was confirmed by the amounts of viral
DNA and protein synthesis in the lymph nodes (Figs. 6A and
7A) as well as other tissues (data not shown) in the PCV2-
inoculated mice. Therefore, we used BALB/c mice as an
animal model for inhibiting PCV2 infection by RNAi in vivo.
The study described herein shows that RNAi induced by
plasmid-borne small interfering RNAs can be used to inhibit
J. Liu et al. / Virology 347 (2006) 422–433430replication of a porcine pathogen in a mouse model system for
12 days after injection. The antiviral treatment decreased viral
expression in the inguinal lymph node and attenuated lymph
node lesions in PCV2-infected mice and thus may be
applicable as a therapeutic strategy for naturally occurring
PCV2 infection.
In conclusion, we show that shRNA can be designed to
induce an antiviral effect on PCV2 DNA replication and
protein synthesis both in cultured cells and in animal model.
These data demonstrate that RNAi is a potential prophylaxis
and therapy for PCV2 infection.
Materials and methods
Virus and cells
The permanent PK15 cell line, which was free of PCV, was
maintained in minimal essential medium (MEM, Gibco)
supplemented with 5% heat-inactivated fetal bovine serum
(FBS), 5% L-glutamine, 100 U/ml of penicillin G, and 100 Al/
ml streptomycin at 37 -C in a humidified 5% CO2 incubator.
The PCV2 virus strain BJW (Liu et al., 2005) was used in the
study.
siRNA target sequences and vector construction
The mammalian expression vector RNAi-Ready pSIREN
(pSIR) (Clontech, BD) was used for the expression of
siRNA. Six specific anti-PCV2 shRNA expression plasmids
were constructed to target ORF1 and ORF2 genes of the
PCV2 strain BJW (GenBank accession no. AY847748)
genome: pSIR1 (targeting sequence, nt F527 to F545), 5V-
AATGCAGAAGCGTGATTGG-3V; pSIR2 (nt F590 to F608),
5V-AAGCAAATGGGCTGCTAAT-3V; pSIR3 (nt F624 to
F642), 5V-ACCACATACTGGAAACCAC-3V; pSIR4 (nt
R1612 to R1594), 5V-AAATGGCATCTTCAACACC-3V; pSIR5
(nt R1429 to R1411), 5V-GGTTGAATTCTGGCCCTGC-3V;
and pSIR6 (nt R1307 to R1289), 5V-ACTACTCCTCCCGC-
CATTC-3V (Fig. 1A). The suffix (F or R) of the oligonucleotide
indicates the orientation of the targeting sequence. F indicates
forward direction from nt 0 to 1767, while R indicates reverse
direction from nt 1767 to 0. A nonspecific shRNA expression
vector, pVP2 (5V-CCTACCTGAGCTGGCCTAA-3V), targeting
capsid protein VP2 gene of porcine parvovirus, was con-
structed as a negative control. These sequences were all
analyzed by a BLAST search of the GenBank database to
avoid similar sequences found in any other genes but share
100% homology within the published PCV2 strains as well.
Oligonucleotides were synthesized and inserted into the pSIR
vector in the BamHI and EcoRI sites according to the
manufacturer’s instructions.
Transfection and infection
The transfection of shRNAs was performed under optimal
conditions. Briefly, PK15 cells were seeded and grown at 37 -C
overnight. When cells reached 60 to 70% confluency, theywere transfected with shRNA expression plasmids with
Lipofectamine reagent (Invitrogen). Following 24 h of trans-
fection, cells were washed and infected with PCV2 strain BJW
at the indicated multiplicity of infection (MOI) for 1 h. The
cells were then overlaid with complete medium and were
incubated at 37 -C in 5% CO2. Cells were additionally treated
with 300 mM d-glucosamine at 24 h after infection as
described previously (Tischer et al., 1987). At 48 h post-
infection, they were analyzed by IFA, and supernatants and cell
lysates were collected for PCR analysis and Western blotting,
respectively.
Indirect fluorescence assay (IFA)
At 24 h of post-transfection with shRNA expression
plasmids, PK15 cells grown on 24-well plate were incubated
with the PCV2 for 60 min at 37 -C at an MOI of 1 TCID50 and
added MEM for incubation. Following the incubation at 37 -C,
cells at 48 h post-infection were washed with PBS and fixed for
30 min at room temperature (RT) with 4% paraformaldehyde
(PFA) in PBS. After fixation, the cells were blocked by PBS
with 3% BSA at RT for 1 h. Primary antibody, porcine anti-
PCV2 antibody, was diluted in PBS with 3% BSA and
incubated with the cells for 1 h at 37 -C. After washing with
PBS, the cells were incubated with rabbit anti-porcine
fluorescein isothiocyanate (FITC)-conjugated antibody (Sig-
ma) diluted in PBS with 3% BSA for 1 h at 37 -C. The cells
were washed three times with PBS and examined using a
fluorescence microscope. Cells positive for PCV2 viral
antigens were counted in six fields of view.
Flow cytometry
PK15 cells were harvested and fixed for 30 min in a 2%
PFA solution. Nonspecific binding was reduced by exposure to
10% equine serum for 30 min and three washes with
fluorescence-activated cell sorter (FACS) wash buffer (phos-
phate-buffered saline with 1% fetal calf serum and 0.1%
sodium azide) prior to incubation with a 1:200 dilution of
porcine against PCV2 antibody for 30 min at RT. The cells
were then washed three times with FACS buffer and incubated
at RT with a 1:100 dilution of FITC-conjugated anti-swine IgG
(Sigma) for 30 min. After incubation, the cells were washed
three times with FACS buffer and resuspended in 400 Al of
FACS buffer before acquisition and analysis on a FACScalibur
instrument (Becton Dickinson) using WinMDI 2.8 software
(Purdue University Cytometry Laboratories).
Western blotting
Western blot analysis was performed after the cells were
harvested by centrifugation at 500  g for 8 min. The pellets
were lysed for 10 min on ice in 150 Al lysis buffer [20 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, pH 8.0, 1%
Triton X-100, 10% glycerol, 1 mM PMSF, 5 mM DTT, and 20
Ag/ml of the proteinase inhibitor cocktail (Novagen)]. Lysates
were then collected by centrifugation at 14,000  g for 10 min
J. Liu et al. / Virology 347 (2006) 422–433 431at 4 -C and the concentration was measured. Twenty
micrograms of total cellular protein from each sample was
resolved on 10 or 12% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and blotted onto nitrocellulose (NC) membranes
(Stratagene) with a semidry transfer cell (Bio-Rad Trans-Blot
SD). The membranes were blocked for 2 h at RT in blocking
buffer TBST (20 mM Tris–HCl [pH 7.4], 150 mM NaCl, 0.1%
Tween-20) containing 5% skim milk powder to prevent
nonspecific binding and then incubated with mouse anti-
ORF1, anti-ORF2 antibody (Liu et al., 2005), or monoclonal
antibody against human glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) (Chemicon International, Inc., CA, USA) at
RT for 2 h. Then, the membranes were washed three times with
TBST and incubated for 1 h at RTwith horseradish-peroxidase-
conjugated anti-mouse secondary antibody (DAKO) diluted in
blocking buffer (1:2000). After washing, the membrane was
reacted with 3,3V-diaminobenzidine tetrahydrochloride (Pierce,
Rockford, Ill., USA) substrate and then stopped with distilled
water.
PCR
Newly synthesized viral DNA in cell culture was assayed by
PCR as elsewhere described (Cheung, 2003b). Briefly, the
supernatants of infected PK15 cells after being transfected with
shRNA-expressing plasmids 72 h post-transfection were used
as templates for PCR amplification. The sense primer 1446F: 5V-
TGTAGTATTCAAAGGGTATAGAGA-3V and antisense prim-
er 420R: 5V-TCACAGCAGTAGACAGGTCACTCCG-3V were
used for amplifying PCV2 DNA. The PCR consisted of an
initial enzyme activation step at 94 -C for 15 min followed by
35 cycles of denaturation at 94 -C for 45 s, annealing at 52 -C
for 45 s, extension at 72 -C for 1 min, and a final extension at
72 -C for 10 min. The PCR product was electrophoresed in
1% agarose gel and photographed.
Real-time RT-PCR
Total cell RNAswere prepared fromvirus-infected PK15 cells
72 h after being transfected with shRNA-expressing plasmids by
using Trizol RNA Extract reagent (Invitrogen) for reverse
transcription (RT)-PCR. The RNA samples were incubated with
DNase I for 60 min at 37 -C to remove any contaminating
viral DNA. The following primers were used: F223, 5V-
TCCAGGGGTTCGCTAA-3V, and R412, 5V-GTAGACAGGT-
CACTCCG-3V, for PCV2-ORF1; R1566, 5V-ATCAAGCGAAC-
CACAG-3V, and F1317, 5V-GGTCATAGGTGAGGGC-3V, for
PCV2-ORF2; and sense, 5V-CATCACTGCCACCCAGAAGA-
3V, and antisense, 5V-GCTGTAGCCAAATTCGTTGT-3V, for
GAPDH. cDNAs were reverse transcribed from total RNAs
by the use of antisense primers and the first-strand synthesis
system (AMV Reverse Transcriptase kit, Roche). Quantitative
real-time PCRs were performed on a LightCycler (Roche).
The amplification protocol followed the instructions of a
TaqMan Gold PCR kit. Each sample was run in triplicates.
The relative amount of target gene mRNA was normalized to
that of GAPDH mRNA in the same sample.Viral challenge assay in BALB/c mice
Fifty BALB/c mice of 8 weeks of age were randomly
assigned into five rooms of 10 animals each. Mice in group 1
were uninoculated and served as negative controls. pSIR3,
pSIR6, and pVP2 expression plasmids (10 Ag per mouse) were
injected via both tail vein and intramuscular routes to mice in
groups 2 to 4, respectively. Mice in group 5 was served as
positive controls. After 24 h, all mice in groups 2 to 5 were
each inoculated intranasally and interperitoneally with about
105 TCID50 of the PCV2 strain BJW. The animals were
monitored daily for clinical signs of disease. At 5 and 11 days
post-infection, five mice were randomly selected from each
group and necropsied. Inguinal lymph nodes were collected
during necropsy and processed for histological examination
and in situ hybridization (ISH) as well as immunohistochem-
ical (IHC) staining.
For histological examination, inguinal lymph nodes were
collected and fixed by immersion in 4% PFA. Fixed samples
were dehydrated, embedded in paraffin wax, and sectioned at 5
Am then stained with hematoxylin and eosin (HE). Lymph node
scores were assessed for depletion of lymphoid cells, infiltra-
tion by histocytic cells, and/or the presence of multinucleated
cells.
For ISH, a PCV2-specific oligoprobe was used for
demonstration of PCV2 nucleic acid. Briefly, a 253 bp DNA
fragment from ORF2 of PCV2 was amplified using a pair of
primers: 5V-ATCAAGCGAACCACAGTCAAAAC-3V and 5V-
GGTCATAGGTGAGGCTGTGGCC-3V. The specific oligop-
robe was labeled with digoxigenin (DIG) (Roche). After
deparaffinization and rehydration, the lymph node sections
were proteolytically digested with 10 Ag/ml of proteinase K in
PBS buffer for 15 min at 37 -C and then post-fixed with 0.4%
PFA in PBS for 30 min at 4 -C. After acetylation, the slides
were prehybridized in hybridization buffer (50% formamide,
5 SSC, 50 Ag/ml denatured salmon sperm DNA) for 120 min
at 37 -C followed by overnight hybridization at 42 -C with the
DIG-labeled DNA probe at a concentration of 300 ng/ml. After
post-hybridization washes, the slides were incubated with anti-
DIG (Roche) (150 Al of 1:5000 diluted in buffer [10% fetal calf
serum; 100 mM Tris–HCl; 150 mM NaCl, pH 7.5]) overnight
at 4 -C. The slides were washed, incubated with Nitro Blue
Tetrazolium-BCIP (5-bromo-4-chloro-3-indolyphosphate) mix-
ture for color development, and then mounted for examination
under the microscopy.
For IHC, a polyclonal anti-PCV2 antibody was used to
detect the presence of PCV2 viral antigen. Briefly, tissue
sections were deparaffinized and rehydrated through graded
alcohol. Endogenous peroxidase activity was inhibited by
flooding the slides with 3% H2O2 in 1% Triton X-PBS for 10
min. After being blocked in 5% normal mouse serum for 1 h at
RT, the slides were incubated with purified PCV2 antibody
(1:100) overnight at RT followed by incubation with a
secondary biotinylated anti-swine IgG (1:200) for 1 h at RT.
An avidin–biotin peroxidase (ABC) method (Pierce, IL, USA)
diluted in 1:100 was applied for 1 h at RT. The sections were
finally incubated in diaminobenzidine (DAB)–hydrogen per-
J. Liu et al. / Virology 347 (2006) 422–433432oxide solution for 5 min and counterstained with 1% Methyl
Green, dehydrated and mounted with Permount (Fisher
Scientific Inc.), and examined microscopically.
Statistical analysis
Results are presented as averages T standard deviations or
standard errors of the means, as indicated. Statistical compar-
isons are made by using Student’s t test, and differences
between groups were considered significant if the P value was
<0.05.
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